Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriele Buda

Showing results (1-10 of 132) with videos related to

Pageof 14
Sort By:
Journal of Clinical Medicine|March 28, 2024
Cardiovascular Toxicity of Antineoplastic Treatments in Hematological Diseases: Focus on Molecular Mechanisms to Improve Therapeutic ManagementSerena Barachini, Gabriele Buda, Iacopo Petrini
Lancet (London, England)|April 22, 2008
Folic acid fortification and cancer riskGabriele Buda, Enrico Orciuolo, Valentina Maggini, et al.
European Heart Journal. Case Reports|January 9, 2020
Rituximab as a novel treatment for heart failure: evidence from a case seriesAlberto Aimo, Antonio Tavoni, Gabriele Buda, et al.
Annals of Hematology|June 8, 2013
Primary non-Hodgkin lymphoma in the pterygopalatine fossa. A peculiar diagnosis with a minimally invasive endoscopic approachVeronica Seccia, Mario Pietrini, Tommaso Briganti, et al.
Cellular Oncology (Dordrecht, Netherlands)|August 9, 2019
Tumor dormancy as an alternative step in the development of chemoresistance and metastasis - clinical implicationsFederico Rossari, Cristina Zucchinetti, Gabriele Buda, et al.
Hematological Oncology|April 9, 2024
Novel monoclonal antibodies: A really specific therapy for light chain amyloidosisMaria Livia Del Giudice, Sara Galimberti, Gabriele Buda
Cancer Immunology, Immunotherapy : CII|November 4, 2023
Beyond BCMA, why GPRC5D could be the right way: treatment strategies with immunotherapy at relapse after anti-BCMA agentsMaria Livia Del Giudice, Sara Galimberti, Gabriele Buda
British Journal of Haematology|November 19, 2009
Fludarabine, Bortezomib, Myocet and rituximab chemotherapy in relapsed and refractory mantle cell lymphomaEnrico Orciuolo, Gabriele Buda, Matteo Pelosini, et al.
Mediterranean Journal of Hematology and Infectious Diseases|March 14, 2025
How First-Line Therapy is Changing in Transplant-Eligible Multiple Myeloma PatientsYasmine Houbaida, Maria Livia Del Giudice, Sara Galimberti, et al.
Pharmaceuticals (Basel, Switzerland)|February 26, 2025
Monoclonal Antibodies in Relapsed-Refractory Multiple MyelomaIlaria Sorgiovanni, Maria Livia Del Giudice, Sara Galimberti, et al.
Pageof 14

Showing results (1-10 of 132) with videos related to

Sort By:
Pageof 14
Journal of Clinical Medicine|March 28, 2024
Cardiovascular Toxicity of Antineoplastic Treatments in Hematological Diseases: Focus on Molecular Mechanisms to Improve Therapeutic ManagementSerena Barachini, Gabriele Buda, Iacopo Petrini
Lancet (London, England)|April 22, 2008
Folic acid fortification and cancer riskGabriele Buda, Enrico Orciuolo, Valentina Maggini, et al.
European Heart Journal. Case Reports|January 9, 2020
Rituximab as a novel treatment for heart failure: evidence from a case seriesAlberto Aimo, Antonio Tavoni, Gabriele Buda, et al.
Annals of Hematology|June 8, 2013
Primary non-Hodgkin lymphoma in the pterygopalatine fossa. A peculiar diagnosis with a minimally invasive endoscopic approachVeronica Seccia, Mario Pietrini, Tommaso Briganti, et al.
Cellular Oncology (Dordrecht, Netherlands)|August 9, 2019
Tumor dormancy as an alternative step in the development of chemoresistance and metastasis - clinical implicationsFederico Rossari, Cristina Zucchinetti, Gabriele Buda, et al.
Hematological Oncology|April 9, 2024
Novel monoclonal antibodies: A really specific therapy for light chain amyloidosisMaria Livia Del Giudice, Sara Galimberti, Gabriele Buda
Cancer Immunology, Immunotherapy : CII|November 4, 2023
Beyond BCMA, why GPRC5D could be the right way: treatment strategies with immunotherapy at relapse after anti-BCMA agentsMaria Livia Del Giudice, Sara Galimberti, Gabriele Buda
British Journal of Haematology|November 19, 2009
Fludarabine, Bortezomib, Myocet and rituximab chemotherapy in relapsed and refractory mantle cell lymphomaEnrico Orciuolo, Gabriele Buda, Matteo Pelosini, et al.
Mediterranean Journal of Hematology and Infectious Diseases|March 14, 2025
How First-Line Therapy is Changing in Transplant-Eligible Multiple Myeloma PatientsYasmine Houbaida, Maria Livia Del Giudice, Sara Galimberti, et al.
Pharmaceuticals (Basel, Switzerland)|February 26, 2025
Monoclonal Antibodies in Relapsed-Refractory Multiple MyelomaIlaria Sorgiovanni, Maria Livia Del Giudice, Sara Galimberti, et al.
Pageof 14